Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243109 | 0.90 | ADORA2A (0.63) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL1401979 | 0.89 | ADORA2A (0.92) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL4559021 | 0.88 | ADORA2A (0.66) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL1402000 | 0.88 | ADORA2A (0.66) | ADORA2AADORA3 | |
| SCHEMBL242951 | 0.88 | ADORA2A (0.74) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL242489 | 0.88 | ADORA2A (0.74) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL242824 | 0.87 | ADORA2A (0.93) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL4125143 | 0.87 | ADORA2A (0.67) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL4117864 | 0.86 | ADORA2A (0.72) | ADORA2AADORA3ADORA2BADORA1 | |
| Trifluoroacetic Acid SCHEMBL4481819 | 0.85 | ADORA2A (0.63) | ADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA2B 1829/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA2B 1829/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA2A 2741/4885ADORA3 795/4885ADORA2B 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.